Elie Lily (Lee) Q1 2025 profits

Eli Lily Thursday I mentioned Revenue in the first quarter and profits that have been estimated as a request on Weight loss and diabetes drugs It rose, but it reduced the entire year profit instructions due to the fees related to the last cancer treatment deal.

The drug giant now expects that its modified financial profits will range between 20.78 dollars and $ 22.28 per share, a decrease from previous directives from $ 22.50 to $ 24 per share. Eli Lily said that the review reflects a $ 1.57 billion deal fees registered in the first quarter, which is primarily linked to its acquisition of some oral cancer medicine from scorpion treatments.

The company maintained its financial sales instructions 2025 from 58 billion dollars to 61 billion dollars. Eli Lily said the guidance reflects the president Donald TrumpCurrent definition tariffs starting from May 1, but it does not include planned fees on imported drugs in the United States

In an interview with CNBC, CEO of Eli Lilly Dave Ricks said that the company and other drug makers already announce Investments in manufacturing in the United StatesIt is one of the Trump administration’s declared targets for definitions.

“I think the threat of definitions in fact already restores critical supply chains to the important industries, potatoes and medicines,” Rex said. “Do we need tooth (definitions?) I am not sure.”

He added that Eli Lily wants to see less permanent tax rates in the United States, especially 15 % for local production. Rex said that low taxes have prompted many drug makers to manufacture in “low -tax islands like Ireland, Singapore and Switzerland, and could return if there is an economic incentive.”

Elie Lily’s diabetes treatment topped expectations in the first quarter, as it achieved revenue of $ 3.84 billion. This is 113 % of the same last period.

Zepbound also won the company’s weight loss over estimates, and seized $ 2.31 billion sales per quarter. This is more than a quadruple amount of $ 517.4 million, which was brought by treatment a year ago, when it just entered the United States market.

Analysts expected Montaru and Zepbound 3.81 billion dollars and $ 2.28 billion in sales, respectively, according to street estimates.

The shares of the company decreased by 5 % in the pre -market trade.

Here is what Elie Lily told for the first quarter compared to what Wall Street expected, based on a survey of analysts by LSEG:

• Arrow’s profits: $ 3.34 amended for $ 3.02 expected
• profit: 12.73 billion dollars compared to 12.67 billion dollars expected

The company recorded revenues in the first quarter of $ 12.73 billion, an increase of 45 % over the same last period.

Sales in the United States jumped by 49 % to 8.49 billion dollars. Eli Lily said this was driven by an increase of 57 % in size – or the number of recipes or units sold – for Zepbound and Mountjaro. The company said this was partially compensated by the low prices of the achieved drugs.

The pharmaceutical giant of the net income of $ 2.76 billion, or $ 3.06 per share, for the first quarter. This compares with the net income of $ 2.24 billion, or $ 2.48, a year ago.

With the exception of the one -time elements associated with the value of incisive assets and other modifications, El Lilly has published $ 3.34 per share for one quarter.

The demand in the United States still outperformed the offer from Zepbound and Mountjaro during the past year. Each of the alleged tonsils treats intestinal hormones for some bowel hormones to reduce a person’s appetite and regulate blood sugar.

The popularity of these injection drugs has forced both Eli Lily and her opponent Novo Nordsk To invest billions of dollars to increase the manufacturing capacity to treat it.

It seems that efforts are paid off: Food and Drug Administration in December Reaffirm To announce the American deficiency in Turzopatide – the active ingredient in Zepbound and Mounjaro – End. This decision is effectively prohibited Double pharmacies From marketing and selling cheaper and non -approved versions of Tirzepatide.

This story is developing. Please check again for updates.